2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-135517
    RXP470.1 891198-31-5 99.60%
    RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a Ki of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification.
    RXP470.1
  • HY-138201
    IM-93 1173657-73-2 ≥99.0%
    IM-93 inhibits ferroptosis and NETosis with an IC< sub>50 of 0.45 µM for cell death inhibition.
    IM-93
  • HY-138822
    2,3-Diphospho-D-glyceric acid pentasodium salt 102783-53-9
    2,3-Diphospho-D-glyceric acid pentasodium salt is a highly anionic polyphosphorus compound. 2,3-Diphospho-D-glyceric acid is present in the concave center of red blood cells, it binds hemoglobin to reduce its oxygen affinity. 2,3-Diphospho-D-glyceric acid is an endogenous, selective inhibitor of vascular calcification (VC) and significantly delays the formation of crystalline calpain particles (CPP). 2,3-Diphospho-D-glyceric acid also inhibits calcification in mouse vascular smooth muscle cell line (MOVAS) without cytotoxic effects.
    2,3-Diphospho-D-glyceric acid pentasodium salt
  • HY-139419
    Bimatoprost grenod 1194396-71-8 98.34%
    Bimatoprost grenod (NCX 470) is a second-generation nitric oxide (NO)-donating prostaglandin analogue. Bimatoprost grenod effectively lowers intraocular pressure (IOP) in animal models of ocular hypertension and glaucoma by activating bimatoprost-mediated uveoscleral outflow and NO mediated conventional outflow. Bimatoprost grenod can be used for the research of cular hypertension and glaucoma.
    Bimatoprost grenod
  • HY-144652
    IDO1-IN-19 2328099-11-0 98.52%
    IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC50 of CYP2C9 of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC50s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases.
    IDO1-IN-19
  • HY-149453
    MCUF-651 2747162-85-0 99.85%
    MCUF-651 is an orally active guanylyl cyclase A receptor (GC-A) positive allosteric modulator (PAM) (KD: 397 nM ). MCUF-651 binds to GC-A and selectively enhances the binding of atrial natriuretic peptide (ANP) to GC-A. MCUF-651 enhances ANP-mediated cGMP generation in human cardiac, renal, and fat cells. MCUF-651 inhibits cardiomyocyte hypertrophy.
    MCUF-651
  • HY-149720
    GRL018-21
    GRL018-21 is a potent and highly selective G protein-coupled receptor kinase 5 (GRK5) inhibitor with an IC50 value of 10 nM.
    GRL018-21
  • HY-153977
    GLX481304 701224-63-7 ≥99.0%
    GLX481304 is a specific inhibitor of Nox-2 and -4, with IC50s of 1.25 μM. GLX481304 suppresses ROS production in isolated mouse cardiomyocytes and improves cardiomyocyte contractility. GLX481304 can be used for research of ischemic injury to the heart.
    GLX481304
  • HY-155773
    VU534 923509-20-0 98.53%
    VU534 is a NAPE-PLD activator, with an EC50 of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH (IC50 of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study [1] .
    VU534
  • HY-162345
    CK-963 2851991-63-2 99.67%
    CK-963 is an activator for cardiac troponin (cTnC) with Ki of 11.5 μM. CK-963 exhibits activity in enhancing cardiac contractility in Sprague-Dawley rats.
    CK-963
  • HY-163348
    FXIIa-IN-4 98.87%
    FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC50 of 0.032 μM, 0.30 μM, ＞50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant.
    FXIIa-IN-4
  • HY-17356R
    Fenofibrate (Standard) 49562-28-9 99.91%
    Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate (Standard)
  • HY-17468S
    Bumetanide-d5 1216739-35-3 99.82%
    Bumetanide-d5 is a deuterium labeled Bumetanide. Bumetanide is a selective Na+-K+-Cl- (NKCC1) inhibitor, weakly inhibits NKCC2, with  IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively[1].
    Bumetanide-d5
  • HY-18071A
    BI-9627 hydrochloride 1422252-46-7 98.01%
    BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury.
    BI-9627 hydrochloride
  • HY-19414A
    (R)-MLN-4760 305335-29-9 99.51%
    (R)-MLN-4760, the R-enantiomer of MLN-4760, is an ACE2 inhibitor, with an IC50 of 8.4 μM. (R)-MLN-4760 is the less active isomer.
    (R)-MLN-4760
  • HY-50903S
    Rivaroxaban-d4 1132681-38-9 98.91%
    Rivaroxaban-d4 is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2].
    Rivaroxaban-d4
  • HY-A0064S
    Verapamil-d3 hydrochloride 2714485-49-9 99.57%
    Verapamil-d3 (hydrochloride) is the deuterium labeled Verapamil hydrochloride. Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].
    Verapamil-d3 hydrochloride
  • HY-A0144A
    Etilefrine hydrochloride 943-17-9 99.81%
    Etilefrine hydrochloride, a sympathetic agent, is an α and β adrenergic receptors agonist. Etilefrine hydrochloride also is an AMPK activator. Etilefrine hydrochloride can be used for the research of postural hypotension and chylothorax.
    Etilefrine hydrochloride
  • HY-A0230A
    Spirapril hydrochloride 94841-17-5
    Spirapril (SCH 33844) hydrochloride is a potent angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure.
    Spirapril hydrochloride
  • HY-A0236A
    Aprindine hydrochloride 33237-74-0 98.96%
    Aprindine hydrochloride is a class I-b anti-arrhythmic agent and a hERG channel blocker with an IC50 of 0.23 μM. Aprindine hydrochloride has inhibitory effects on Na+/Ca2+ exchanger currents, which is partly responsible for their antiarrhythmic and cardioprotective effects. Aprindine hydrochloride is widely used for trial and ventricular tachyarrhythmias research research.
    Aprindine hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity